Inceptionr LLC Takes $357,000 Position in TG Therapeutics, Inc. $TGTX

Inceptionr LLC purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,732 shares of the biopharmaceutical company’s stock, valued at approximately $357,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of TGTX. Royal Bank of Canada increased its holdings in TG Therapeutics by 16.4% during the 1st quarter. Royal Bank of Canada now owns 75,692 shares of the biopharmaceutical company’s stock worth $2,985,000 after purchasing an additional 10,660 shares during the period. NewEdge Advisors LLC lifted its holdings in shares of TG Therapeutics by 9.6% in the 1st quarter. NewEdge Advisors LLC now owns 7,593 shares of the biopharmaceutical company’s stock worth $299,000 after buying an additional 665 shares during the period. Goldman Sachs Group Inc. grew its position in shares of TG Therapeutics by 21.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock worth $75,683,000 after buying an additional 345,059 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of TG Therapeutics by 5.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 287,059 shares of the biopharmaceutical company’s stock worth $11,319,000 after buying an additional 14,689 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in shares of TG Therapeutics by 86.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 573 shares during the period. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Trading Down 0.5%

TGTX opened at $55.75 on Tuesday. The company has a current ratio of 5.81, a quick ratio of 5.12 and a debt-to-equity ratio of 1.28. The firm has a market cap of $8.53 billion, a price-to-earnings ratio of 19.49, a PEG ratio of 1.40 and a beta of 1.60. TG Therapeutics, Inc. has a 12 month low of $25.28 and a 12 month high of $59.30. The stock has a fifty day moving average price of $49.34 and a 200-day moving average price of $38.26.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The company had revenue of $204.92 million for the quarter, compared to the consensus estimate of $200.33 million. During the same period in the previous year, the business earned $0.03 EPS. TG Therapeutics’s revenue for the quarter was up 69.5% compared to the same quarter last year. As a group, equities research analysts anticipate that TG Therapeutics, Inc. will post 1.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Bank of America lifted their price objective on TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a report on Tuesday, July 7th. Zacks Research raised shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, June 1st. Weiss Ratings raised shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, May 1st. B. Riley Financial boosted their price target on shares of TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a report on Monday. Finally, HC Wainwright upped their price target on shares of TG Therapeutics from $70.00 to $77.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, TG Therapeutics presently has an average rating of “Hold” and an average price target of $58.50.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small?molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.